Select Page

Alecensa Reduces Recurrence, Mortality Risk in Lung Cancer Subset
“Patients with resected ALK-positive non-small cell lung cancer (NSCLC) experienced a significant improvement in disease-free survival when treated with Alecensa (alectinib), an oral ALK inhibitor, according to recent trial results”.

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer
“MADRID, Oct. 21, 2023 /PRNewswire/ — MEDSIR, a company specializing in the strategic design of independent clinical research, today presented the results of three new studies at the European Society for Medical Oncology (ESMO 2023), one of the most prestigious oncology platforms for clinicians, researchers and healthcare industry representatives in Europe and with global influence: LUPER, focused on patients with small-cell lung cancer; and two translational studies extending the results of the PHERGain study, focused on HER2-positive breast cancer.”

Krazati-Keytruda Combo Boasts 63 Percent Response Rate in Frontline Lung Cancer Study at ESMO
“NEW YORK – Mirati Therapeutics’ KRAS inhibitor Krazati (adagrasib) with Merck’s checkpoint inhibitor Keytruda (pembrolizumab) was well-tolerated and effective as a frontline treatment for KRAS G12C-mutant advanced non-small cell lung cancer, according to data presented at the European Society for Medical Oncology Congress on Friday.”

SF hospital pioneering new technique to diagnose, treat lung cancer
“SAN FRANCISCO – A hospital in San Francisco is using a revolutionary new procedure to treat lung cancer. This new technique involves diagnosing, locating and treating the cancer all in one procedure.”

Nivolumab regimen improves outcomes in resectable non-small cell lung cancer
“MADRID — The addition of nivolumab to neoadjuvant chemotherapy, followed by adjuvant nivolumab, improved outcomes for patients with untreated resectable non-small cell lung cancer, randomized phase 3 study results showed.”

Tarlatamab active in previously treated small cell lung cancer
“MADRID — Tarlatamab exhibited antitumor activity among patients with small cell lung cancer who received prior treatment, according to results of the DeLLphi-301 study presented at ESMO Congress.”

What Younger and Middle-Aged Women Need to Know About Lung Cancer
“Lung cancer—historically associated with men and those who smoke—is now being diagnosed more often in younger and middle-aged women, new research suggests.”

Roundtable Roundup: Lung Cancer Biomarkers
“A 66-year-old man presented to his primary care physician complaining of visual disturbances, fatigue, and sporadic headaches. He had a medical history of hypertension managed with candesartan and hyperlipidemia managed with simvastatin in addition to a smoking history of 25 pack-years.”

Analysis of Lung Cancer Patients Presenting Emergently: A Retrospective Examination
“Many lung cancer patients are diagnosed during emergency presentations (EPs) to emergency departments (EDs). For a study, researchers sought to provide an overview of EPs related to lung cancer at a safety-net hospital system.”

GSK highlights new data in non-small cell lung cancer and endometrial cancer at the European Society for Medical Oncology (ESMO) Congress 2023, reinforcing potential of Jemperli (dostarlimab) as a backbone immuno-oncology therapy
“Late-breaking data from head-to-head PERLA trial shows favourable numerical trend in overall survival (OS) results for Jemperli (dostarlimab) plus chemotherapy vs. pembrolizumab plus chemotherapy in first-line metastatic non-squamous non-small cell lung cancer (NSCLC)”

Hypothyroidism May Be Protective Against Lung Cancer
“Hypothyroidism genetically has a protective causal relationship with lung cancer, as well as protective effects on lung adenocarcinoma and squamous cell lung cancer, according to a study in BMC Pulmonary Medicine.”

Alternative Model for Lung Cancer Screening Shows Higher Sensitivity Than Current Model
“A new study published in Cancer found an alternative model to identify patients with lung cancer who are eligible for screening was more accurate than the current method based on United States Preventive Services Task Force (USPSTF) criteria. The USPSTF determines eligibility for lung cancer screening based on age and smoking history. Specifically, individuals who are 50 to 80 years of age or used to smoke and quit 15 years ago or less with 20 pack years of smoking history (eg, 1 pack a day for 20 years, 2 packs a day for 10 years) are eligible for lung cancer screening.1

Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients
”SHANGHAI, Oct. 20, 2023 /PRNewswire/ — Dizal today announced the latest research findings on the efficacy and safety of sunvozertinib in treatment-naïve patients with advanced or metastatic NSCLC with EGFR Exon20ins mutations at the 2023 European Society for Medical Oncology (ESMO) Congress.”

USPSTF, PLCO Lung Cancer Screening Models Similarly Sensitive for Indigenous People
“Eligibility for lung cancer screening did not differ significantly among people who self-reported as Indigenous. These findings were published in Cancer.”